These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9251373)

  • 1. Experience with roxithromycin in visceral leishmaniasis in north Bihar.
    Lal SK; Lal R; Lal S; Lal R; Lal BN
    J Assoc Physicians India; 1996 Sep; 44(9):615-7. PubMed ID: 9251373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of visceral leishmaniasis in India.
    Bora D
    Natl Med J India; 1999; 12(2):62-8. PubMed ID: 10416321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
    Thakur CP; Narayan S; Ranjan A
    Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
    Giri OP; Singh AN
    J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
    Sinha PK; Ranjan A; Singh VP; Das VN; Pandey K; Kumar N; Verma N; Lal CS; Sur D; Manna B; Bhattacharya SK
    J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
    Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
    J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
    Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
    Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
    J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
    Thakur CP
    Trans R Soc Trop Med Hyg; 1984; 78(3):391-8. PubMed ID: 6087515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
    Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy in Kala-azar.
    Singh NK; Jha TK; Singh IJ; Jha S
    J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicoepidemiological profile of kala azar patients in Delhi.
    Mittal V; Bhatia R; Sehgal S
    J Commun Dis; 1989 Dec; 21(4):255-61. PubMed ID: 2638373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kala-azar control programme for remote tribal communities.
    Thakur CP; Frances Sister ; Therese Sister ; Victoria Sister ; Puspa Sister
    World Health Forum; 1994; 15(3):245-7. PubMed ID: 7945751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium antimony resistant cases of kala-azar in and around Patna (south Bihar).
    Sehgal PN; Murmu C; Chatteyee AK
    J Commun Dis; 1988 Jun; 20(2):161-2. PubMed ID: 2853714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.